RecruitingNCT06123962

ALI/ARDS Clinical Sub-phenotyping Study

Acute Lung/ Acute Respiratory Distress Syndrome and Extra-pulmonary Organ Injury Clinical Sub-phenotyping Study


Sponsor

China-Japan Friendship Hospital

Enrollment

1,500 participants

Start Date

Dec 14, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

1. Construct a structured clinical data and biosample information platform for Chinese patients with acute lung injury/ acute respiratory distress syndrome. 2. By deciphering the heterogeneity of patients with acute lung injury/ acute respiratory distress syndrome, achieve clinical, longitudinal physiological, and biological sub-phenotyping to guide individualized precision treatment and improve prognosis.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Meet the diagnostic criteria for Acute Respiratory Distress Syndrome (ARDS) according to the updated global definition in 2023.
  • The patient or their legal representative signs an informed consent form.

Exclusion Criteria2

  • Individuals aged less than 18 years old.
  • Those who refuse to participate in the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURECollect peripheral blood and bronchoalveolar lavage fluid

Peripheral venous blood will be collected and stored from the study participants at a total of five time points: Day 0, Day 1, Day 2, Day 3 after admission to the ICU, and the day of ICU discharge/death. The collection will be conducted after assessing the patients' eligibility for ARDS diagnosis. Each time point will involve the collection of one tube of peripheral venous blood, totaling 5 mL per sample. Within 24 hours after patients' admission to the ICU and meeting the assessment criteria for ARDS diagnosis, bronchoalveolar lavage fluid (BALF) will be collected and retained, totaling 10 mL.


Locations(1)

Jingen Xia

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06123962


Related Trials